標(biāo)題: Titlebook: p53 in the Clinics; Pierre Hainaut,Magali Olivier,Klas G. Wiman Book 2013 Springer Science+Business Media New York 2013 TP53.cancer resear [打印本頁] 作者: fathom 時間: 2025-3-21 19:25
書目名稱p53 in the Clinics影響因子(影響力)
書目名稱p53 in the Clinics影響因子(影響力)學(xué)科排名
書目名稱p53 in the Clinics網(wǎng)絡(luò)公開度
書目名稱p53 in the Clinics網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱p53 in the Clinics被引頻次
書目名稱p53 in the Clinics被引頻次學(xué)科排名
書目名稱p53 in the Clinics年度引用
書目名稱p53 in the Clinics年度引用學(xué)科排名
書目名稱p53 in the Clinics讀者反饋
書目名稱p53 in the Clinics讀者反饋學(xué)科排名
作者: Cupidity 時間: 2025-3-22 00:13 作者: 野蠻 時間: 2025-3-22 01:15 作者: PAEAN 時間: 2025-3-22 05:26 作者: lethargy 時間: 2025-3-22 09:04 作者: Asymptomatic 時間: 2025-3-22 16:35
Assessing , Status in Human Tumors: Lessons from Breast Cancer,on detection methods, and be more applicable in different aspects of clinical decision making. As breast cancer is one of the cancer diseases where . mutation status shows the most significant prognostic impact and clinical potential, the chapter is based on experiences from research on this tumor type.作者: MOCK 時間: 2025-3-22 17:56 作者: Infuriate 時間: 2025-3-23 00:53 作者: COW 時間: 2025-3-23 04:19 作者: 江湖騙子 時間: 2025-3-23 09:26
The p53 Family and Stem Cell Biology,se features are achieved by a fine-tuned control of proliferation and maintenance of the undifferentiated condition. Transcription factors such as Nanog, Sox, and Oct-4 and extrinsic factors (LIF, BMP, and FGF) have been demonstrated to play a critical role in the regulation of stemness. Because ste作者: eucalyptus 時間: 2025-3-23 10:22 作者: 開花期女 時間: 2025-3-23 14:41 作者: 慎重 時間: 2025-3-23 21:41 作者: machination 時間: 2025-3-24 00:50 作者: 自由職業(yè)者 時間: 2025-3-24 04:56
Assessing , Status in Human Tumors: Lessons from Breast Cancer,ssessing . mutation status in human tumors and the most commonly used techniques will be presented to show the advancement and current trends. . status is further discussed in the context of whole genome analysis, which may elucidate the . network, uncover gene profiles to substitute previous mutati作者: 兒童 時間: 2025-3-24 07:30 作者: 外觀 時間: 2025-3-24 14:05
, Gene Therapy for Cancer Treatment and Prevention,r . gene therapy to restore normal p53 function in cancer treatment. Several important principles were elucidated in preclinical tumor models which predicted the outcomes of subsequent clinical trials including synergistic antitumor activity for combined . gene therapy plus DNA damaging chemotherapy作者: interference 時間: 2025-3-24 16:41
Upstream Targets in the p53 Pathway,cancer therapies. Both mutant and wild-type protein can be reactivated via direct binding of small molecules, but it is also possible to achieve this by targeting proteins involved in the regulation of p53. As many tumours contain wild-type p53 protein that is rendered inactive via disruption of its作者: 離開 時間: 2025-3-24 19:24 作者: 指耕作 時間: 2025-3-25 00:01
Targeting Mutant p53 for Improved Cancer Therapy,53-dependent apoptosis in response to oncogenic stress and thus eliminate the tumor. Mutant p53 reactivation may also lead to inhibition of mutant p53 gain-of-function activities that promote tumor growth, and act synergistically with conventional chemotherapeutic agents and radiotherapy. Several sm作者: 非實體 時間: 2025-3-25 06:44 作者: 可卡 時間: 2025-3-25 10:30
Designing p53 Trials: A Surgical Oncologists View,ement among experts as to how new anticancer drugs should be evaluated before they can be used in standard therapy. However, a corresponding algorithm for the clinical implementation of markers does not exist..Before designing a phase III marker trial one must know whether the marker being tested pr作者: 易彎曲 時間: 2025-3-25 11:39 作者: 6Applepolish 時間: 2025-3-25 16:22 作者: 被詛咒的人 時間: 2025-3-25 22:20
, Somatic Mutations: Prognostic and Predictive Value in Human Cancers,edictive value of TP53 mutation status in cancer patients. Despite many studies showing a poor prognosis associated with TP53-mutated status, no consensus results have been produced that could support clinical applications. Here, we review these studies, in particular those performed in the context of specific treatment regimen.作者: definition 時間: 2025-3-26 00:21 作者: sulcus 時間: 2025-3-26 08:14 作者: CULP 時間: 2025-3-26 12:15
Designing p53 Trials: A Surgical Oncologists View,wledge of the underlying scenario is a prerequisite to decide on the optimal marker trial design..We describe a generally applicable algorithm for clinical evaluation of a marker. The algorithm is applied to current knowledge concerning the marker p53.作者: –DOX 時間: 2025-3-26 15:52 作者: GIDDY 時間: 2025-3-26 19:27 作者: 描述 時間: 2025-3-26 21:18
,p53 in the Clinic: A Pathologist’s View,compared to . status assessed by gene sequencing. This explains why p53 as a biomarker remains not so widely used by pathologists except for several well-defined indications detailed in this chapter. P63, a member of the p53 family, is also frequently used in diagnostic pathology as a differentiation marker and will be discussed in this chapter.作者: 最高峰 時間: 2025-3-27 01:53 作者: Flinch 時間: 2025-3-27 09:09
Book 2013 advances on the potential application of p53 into the clinics. The goal of this book is to capture these developments and to appeal to a clinical and medical audience beyond the one which was the primary target of "25 years of p53".作者: BALK 時間: 2025-3-27 11:07
978-1-4899-9217-8Springer Science+Business Media New York 2013作者: nephritis 時間: 2025-3-27 14:20
Pierre Hainaut,Magali Olivier,Klas G. WimanFocuses on recent advances in translational research on p53.Explores the significance of the genetic diversity of p53.Discusses mutations as biomarkers in molecular pathology作者: 無辜 時間: 2025-3-27 18:24
